Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Author(s):
Giulia Magnani
,
Marco Valgimigli
Added:
3 years ago
Dual antiplatelet therapy (DAPT), defined as the use of a P2Y12 receptor inhibitor (clopidogrel, ticagrelor or prasugrel) and aspirin, is required after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).1 Although the use of DES has been shown to reduce the rate of restenosis as compared with bare-metal stents (BMS), there is concern that DES may be associated with a higher…
View more
Author(s):
Benjamin Galper
,
Roxana Mehran
Added:
3 years ago
Acute coronary syndromes (ACS) result from unstable coronary artery plaques that rupture and can lead to coronary ischaemia, unstable angina and myocardial infarction. The treatment goals in ACS focus on reducing ischaemia, preventing further progression of thrombotic plaque by disturbing the milieu of thrombosis and platelet aggregation taking place within the coronary artery and, in the case of…
View more
Author(s):
Timm Bauer
,
Christian Hamm
Added:
3 years ago
Introduction
Antiplatelet therapy is a cornerstone in coronary artery disease (CAD) management. Acetylsalicyclic acid (ASA) has been known for many decades to have antithrombotic efficacy. Already in the 1980’s, the ISIS-2 study demonstrated that ASA reduces mortality in acute myocardial infarction (AMI) by 23 %.1 ASA leads to irreversible inactivation of cyclooxygenase 1 and thereby blocks the…
View more
Author(s):
William R Colyer Jr
,
Christopher J Cooper
Added:
3 years ago
Atherosclerotic renal artery stentosis (RAS) is a frequently recognised cause of secondary hypertension and chronic kidney disease.1–4 Revascularisation of RAS with angioplasty and stenting is often performed with the goals of improved blood pressure control and preserving or improving renal function.5 However, renal artery stenting is sometimes associated with acute worsening of renal function.6…
View more
Author(s):
Sri Raveen Kandan
,
Thomas W Johnson
Added:
3 years ago
Antiplatelet Therapy
Current guidelines support the early administration of oral antiplatelet agents upstream of angiographic assessment and intervention.1 Aspirin is commonly given by the first medical contact and additional oral antiplatelet drugs are administered on arrival in hospital (see Figure 1).
Aspirin
The efficacy of aspirin in acute ST-segment elevation myocardial infarction (STEMI)…
View more
Author(s):
Mohammad Sahebjalal
,
Nick Curzen
Added:
3 years ago
Antiplatelet therapy (APT) represents a major cornerstone in the secondary prevention of coronary artery disease, along with modifying patients’ risk factors. Furthermore, it has been clear, since early unsuccessful regimens, including warfarin and dypiridamole with aspirin, that it is APT that stops coronary stents from clotting off and causing stent thrombosis.1,2 Specifically, the requirement…
View more
Author(s):
Kevin S Tang
,
Shoujit Banerjee
,
George Tang
,
et al
Added:
3 months ago
Author(s):
Marco Valgimigli
Added:
1 year ago
ESC Congress 22 — Prof Marco Valgimigli (Cardiocentro Ticino Foundation, CH) joins us to share the 15-month results from the MASTER DAPT trial (NCT03023020).
This randomised, multi-centre study compared abbreviated antiplatelet with prolonged antiplatelet regimen (aspirin and P2Y12i) aligned with current medical recommendation in high bleeding risk (HBR) patients who received biodegradable…
View more
Author(s):
Jean-Philippe Collet
,
Jochem Wouter van Werkum
Added:
3 years ago
Antiplatelet therapy is the standard of care for patients with acute coronary syndromes (ACS) and/or patients undergoing percutaneous coronary intervention (PCI) with stenting.1–3 Plaque rupture and/or iatrogenic vascular damage during PCI would normally result in the development of intravascular thrombus. Findings across multiple investigations consistently demonstrate the effectiveness of dual…
View more